ABSTRACT
Multiple myeloma (MM) is an incurable malignant plasma cell disorder that constitutes 1% of all cancer and 10% of hematological neoplasms. Its worldwide incidence rates vary from 0.4 to 5 per 100,000, with a higher rate in males, in Western countries, and among African Americans. The incidence of MM increases considerably with age, with a median age at diagnosis of 66 years (age-adjusted incidence rates 2.1 vs. 30.1 in patients aged under and over 65 years, respectively) (1,2). The number of geriatric patients is expected to rise over time because of the increased life expectancy of the normal population.
